Camizestrant Clinical Trials (2026): 10 Studies for Advanced Breast Cancer & Breast Cancer

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

10 Camizestrant clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 8 indications (including Advanced Breast Cancer & Breast Cancer) and 11,816 total planned enrollment. 3 Phase 3 Camizestrant trials and 2 Phase 2 are listed. 6 Camizestrant clinical trials are actively recruiting at 149 U.S. sites across 38 states. Most recent activity: NCT05952557 (May 2037).

Where to Participate: All Camizestrant Trial Sites in the U.S. (149 sites across 38 states)

Every actively recruiting Camizestranttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALResearch SiteDothan36303NCT05952557Map
AZResearch SiteGilbert85234NCT06380751Map
AZResearch SitePhoenix85054NCT05952557Map
AZResearch SiteTucson85745NCT05952557Map
ARResearch SiteFayetteville72703NCT05952557Map
CAResearch SiteDuarte91010NCT05952557Map
CAResearch SiteFountain Valley92708NCT06380751Map
CAResearch SiteFountain Valley92708NCT05952557Map
CAResearch SiteGlendale91206NCT06380751Map
CAResearch SiteIrvine92618NCT05952557Map
CAResearch SiteLa Jolla92093NCT05952557Map
CAResearch SiteLos Angeles90089NCT06380751Map
CAResearch SiteLos Angeles90017NCT05952557Map
CAResearch SiteNewport Beach92663NCT06380751Map
CAResearch SiteWalnut Creek94598NCT05952557Map
CAResearch SiteWest Hollywood90048NCT05952557Map
COResearch SiteAurora80045NCT06380751Map
COResearch SiteLittleton80120NCT05952557Map
COResearch SiteLittleton80129NCT05952557Map
CTResearch SiteNew Haven06510NCT05952557Map
DEResearch SiteNewark19713NCT05952557Map
FLResearch SiteClearwater33756NCT05952557Map
FLResearch SiteFort Myers33901NCT05952557Map
FLResearch SiteGainesville32610NCT05952557Map
FLResearch SiteHollywood33021NCT06380751Map
FLResearch SiteJacksonville32224NCT06380751Map
FLResearch SiteJacksonville32224NCT05952557Map
FLResearch SitePembroke Pines33028NCT05952557Map
FLResearch SitePlantation33322NCT05952557Map
FLResearch SitePlantation33324NCT05952557Map
FLResearch SiteSt. Petersburg33709NCT05952557Map
FLResearch SiteWest Palm Beach33401NCT05952557Map
GAResearch SiteAtlanta30318NCT05952557Map
GAResearch SiteMarietta30060NCT05952557Map
GAResearch SiteThomasville31792NCT05952557Map
ILResearch SiteChicago60611NCT06380751Map
ILResearch SiteChicago60637NCT05952557Map
ILResearch SiteElmhurst60126NCT05952557Map
ILResearch SiteEvanston60201NCT06380751Map
ILResearch SiteNaperville60540NCT05952557Map
ILResearch SiteUrbana61801NCT06380751Map
ILResearch SiteUrbana61801NCT05952557Map
ILResearch SiteWinfield60190NCT06380751Map
INResearch SiteFort Wayne46804NCT05952557Map
IAResearch SiteDes Moines50309NCT05952557Map
KYResearch SiteLouisville40202NCT05952557Map
LAResearch SiteNew Orleans70121NCT05952557Map
MEResearch SiteScarborough04074NCT05952557Map
MDResearch SiteAnnapolis21401NCT05952557Map
MDResearch SiteBethesda20817NCT05952557Map
MDResearch SiteSilver Spring20902NCT06380751Map
MDResearch SiteSilver Spring20904NCT06380751Map
MDResearch SiteTowson21204NCT05952557Map
MAResearch SiteBoston02215NCT06380751Map
MAResearch SiteBoston02111NCT05952557Map
MAResearch SiteBoston02115NCT05952557Map
MIResearch SiteDetroit48202NCT06380751Map
MIResearch SiteDetroit48202NCT05952557Map
MIResearch SiteRoyal Oak48073NCT06380751Map
MIResearch SiteYpsilanti48197NCT05952557Map
MNResearch SiteMinneapolis55416NCT05952557Map
MNResearch SiteRochester55905NCT06380751Map
MNResearch SiteRochester55905NCT05952557Map
MOResearch SiteKansas City64111NCT05952557Map
MOResearch SiteSpringfield65804NCT06380751Map
MOResearch SiteSt Louis63141NCT06188520Map
MOResearch SiteSt Louis63108NCT07427394Map
MOResearch SiteSt Louis63110NCT05952557Map
MOResearch SiteSt Louis63131NCT05952557Map
NEResearch SiteLincoln68506NCT05952557Map
NEResearch SiteOmaha68124NCT05952557Map
NHResearch SiteHooksett03106NCT05952557Map
NHResearch SiteManchester03103NCT05952557Map
NJResearch SiteCamden08103NCT06380751Map
NJResearch SiteNew Brunswick08901NCT05952557Map
NMResearch SiteAlbuquerque87109NCT05952557Map
NMResearch SiteFarmington87401NCT05952557Map
NYResearch SiteBay Shore11706NCT05952557Map
NYResearch SiteEast Syracuse13057NCT05952557Map
NYResearch SiteGreenlawn11740NCT05952557Map
NYResearch SiteMineola11501NCT06380751Map
NYResearch SiteNew Hyde Park11042NCT05952557Map
NYResearch SiteNew York10016NCT06380751Map
NYResearch SiteNew York10065NCT06380751Map
NYResearch SiteNew York10029NCT05952557Map
NYResearch SiteNew York10065NCT05952557Map
NYResearch SiteStony Brook11790NCT06380751Map
NYResearch SiteStony Brook11794NCT05952557Map
NYResearch SiteWhite Plains10601NCT05952557Map
NCResearch SiteCharlotte28204NCT05952557Map
NCResearch SitePinehurst28374NCT05952557Map
NCResearch SiteRaleigh27607NCT05952557Map
NCResearch SiteWinston-Salem27103NCT05774951Map
NCResearch SiteWinston-Salem27103NCT05952557Map
OHResearch SiteCincinnati45255NCT05952557Map
OHResearch SiteCleveland44106NCT05952557Map
OHResearch SiteColumbus43212NCT05952557Map
ORResearch SitePortland97210NCT05952557Map
ORResearch SitePortland97213NCT05952557Map
PAResearch SiteGettysburg17325NCT05952557Map
PAResearch SiteHershey17033NCT06380751Map
PAResearch SitePhiladelphia19104NCT06380751Map
PAResearch SitePhiladelphia19104NCT05952557Map
PAResearch SitePittsburgh15215NCT06380751Map
PAResearch SitePittsburgh15213NCT05952557Map
PAResearch SiteSayre18840NCT05952557Map
PAResearch SiteYork17403NCT05952557Map
RIResearch SiteProvidence02903NCT06188520Map
SCResearch SiteSpartanburg29303NCT05952557Map
SDResearch SiteAberdeen57401NCT05774951Map
SDResearch SiteAberdeen57401NCT05952557Map
SDResearch SitePierre57501NCT05774951Map
SDResearch SiteSioux Falls57105NCT05952557Map
TNResearch SiteChattanooga37404NCT06380751Map
TNResearch SiteKnoxville37909NCT05952557Map
TNResearch SiteKnoxville37920NCT05952557Map
TNResearch SiteMemphis38120NCT05952557Map
TNResearch SiteNashville37201NCT06188520Map
TNResearch SiteNashville37203NCT06380751Map
TNResearch SiteNashville37203NCT07427394Map
TNResearch SiteNashville37203NCT05952557Map
TNResearch SiteNashville37232NCT05952557Map
TXResearch SiteAustin78731NCT05952557Map
TXResearch SiteDallas75246NCT05952557Map
TXResearch SiteEl Paso79902NCT05952557Map
TXResearch SiteFlower Mound75028NCT05952557Map
TXResearch SiteHouston77030NCT06188520Map
TXResearch SiteHouston77030NCT06380751Map
TXResearch SiteHouston77054NCT06380751Map
TXResearch SiteHouston77024NCT05952557Map
TXResearch SiteIrving75063NCT05774951Map
TXResearch SiteSan Antonio78240NCT06380751Map
TXResearch SiteSan Antonio78217NCT05952557Map
TXResearch SiteTyler75702NCT05952557Map
VAResearch SiteCharlottesville22908NCT05952557Map
VAResearch SiteFairfax22031NCT05952557Map
VAResearch SiteMidlothian23114NCT05952557Map
VAResearch SiteNorfolk23502NCT06380751Map
VAResearch SiteNorfolk23502NCT05952557Map
VAResearch SiteRoanoke24014NCT05952557Map
VAResearch SiteWinchester22601NCT05952557Map
WAResearch SitePuyallup98373NCT05952557Map
WAResearch SiteSpokane99202NCT05952557Map
WAResearch SiteTacoma98405NCT06380751Map
WAResearch SiteVancouver98684NCT05952557Map
WVResearch SiteMorgantown26506NCT06380751Map
WVResearch SiteMorgantown26505NCT05952557Map
WIResearch SiteAppleton54911NCT05952557Map
WIResearch SiteMadison53792NCT05952557Map

Camizestrant clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedTotal
P133
P1/P2112
P222
P333

Recruiting Camizestrant clinical trials (6)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT05952557CAMBRIA-2An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)P3Breast Cancer, Early Breast Cancer5,500Oct 2023
NCT05774951CAMBRIA-1A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyP3Breast Cancer, Early Breast Cancer4,300Mar 2023
NCT06380751EvoPAR-BR01Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerP3Advanced Breast Cancer500Aug 2024
NCT07195227CADILLACEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerP2Hormon Receptor Positive Breast Cancer150Mar 2026
NCT07427394SERENA-1bStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerP2Advanced Breast Cancer24May 2026
NCT06188520CYCAD-1A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsP1/P2ER+ HER2- Advanced Breast Cancer564Dec 2023

Camizestrant clinical trials by indication

Advanced Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06380751EvoPAR-BR01P3recruitingSaruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT07427394SERENA-1bP2recruitingStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Breast Cancer, Early Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT05952557CAMBRIA-2P3recruitingAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05774951CAMBRIA-1P3recruitingA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Hormon Receptor Positive Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07195227CADILLACP2recruitingEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Healthy Participants (1)

NCTAcronymPhaseStatusTitle
NCT06547164AZD9833P1completedA Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

ER+ HER2- Advanced Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06188520CYCAD-1P1/P2recruitingA First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Hepatic Impairment (1)

NCTAcronymPhaseStatusTitle
NCT05790304—P1completedStudy to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Healthy Subjects (1)

NCTAcronymPhaseStatusTitle
NCT05551897AZD9833P1completedA Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Ovarian Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04644068PETRAP1/P2active not recruitingStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Camizestrant pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
CAMBRIA-2NCT05952557P3recruitingBreast Cancer, Early Breast Cancer5,500PMID 40017004
CAMBRIA-1NCT05774951P3recruitingBreast Cancer, Early Breast Cancer4,300—
EvoPAR-BR01NCT06380751P3recruitingAdvanced Breast Cancer500—
CADILLACNCT07195227P2recruitingHormon Receptor Positive Breast Cancer150—
SERENA-1bNCT07427394P2recruitingAdvanced Breast Cancer24—

All Camizestrant trials (10)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT05952557CAMBRIA-2An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)P3recruiting5,500AstraZenecaOct 2023
NCT05774951CAMBRIA-1A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyP3recruiting4,300AstraZenecaMar 2023
NCT06380751EvoPAR-BR01Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerP3recruiting500AstraZenecaAug 2024
NCT07195227CADILLACEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerP2recruiting150MedSIRMar 2026
NCT07427394SERENA-1bStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerP2recruiting24AstraZenecaMay 2026
NCT06188520CYCAD-1A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsP1/P2recruiting564AstraZenecaDec 2023
NCT04644068PETRAStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesP1/P2active not recruiting702AstraZenecaNov 2020
NCT06547164AZD9833A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsP1completed40AstraZenecaAug 2024
NCT05790304Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsP1completed22AstraZenecaFeb 2023
NCT05551897AZD9833A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleP1completed14AstraZenecaOct 2022

Camizestrant clinical trials: frequently asked questions

How many Camizestrant clinical trials are there?
10 Camizestrant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 3 are marked completed.
Are Camizestrant clinical trials recruiting in 2026?
Yes — 6 Camizestrant trials are actively recruiting in 2026, with 149 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Camizestrant being studied for?
Camizestrant is being studied for Advanced Breast Cancer, Breast Cancer, Breast Cancer, Early Breast Cancer, Cervical Cancer, Colorectal Cancer and 16 more. The trials are grouped by indication on this page.
What phase is Camizestrant in?
Camizestrant clinical trials span 3 Phase 3, 2 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Camizestrant clinical trials?
The lead sponsor across the most Camizestrant trials is AstraZeneca, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Camizestrantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

Camizestrant overviewCamizestrant evidence & publications